Introduction: Finasteride is one of the most common drugs used in androgenetic alopecia. The literature discusses the sexual side effects of the drug; however, in practice there is little evidence to support this. The aim of the present study was to investigate the sexual dysfunction in patients taking finasteride 1 mg for androgenetic alopecia.
Methods: A questionnaire, based on the International Index of Erectile Function, was given to approximately 586 patients with androgenetic alopecia who were being treated with finasteride 1 mg for an average of 16 weeks. These patients were compared to an age-related control group who were attending the Dermatology Out Patients Department for various other skin ailments not related to hair disorders.
Results: Statistical analysis of the results showed no significant difference in the scores between patients taking finasteride and the control group.
Conclusion: Analysis showed no significant difference in sex-related problems with that of patients taking finasteride and age matched controls, suggesting that sex-related issues are not a side effect of finasteride.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4674453 | PMC |
| http://dx.doi.org/10.1007/s13555-015-0084-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Unveiling the Effect of Age and IgE Level on Alopecia Areata: Insights from Comparative RNAseq Analysis.
Clin Cosmet Investig Dermatol
January 2025
Department of Dermatology, Dermatology Hospital, Southern Medical University, Guangzhou, 510091, People's Republic of China.
Background: Alopecia areata (AA) is a common autoimmune disease, causes sudden hair loss on the scalp, face, and sometimes other areas of the body. Previous studies have suggested more severe manifestations and higher recurrence rates in children than in adults. Moreover, pediatric AA patients with atopic predisposition often exhibit elevated IgE levels, early onset, and a poor prognosis.
View Article and Find Full Text PDFTrending Psychiatric Comorbidities in Patients with Alopecia Areata in the United States from 2002 to 2019.
J Clin Aesthet Dermatol
January 2025
Dr. Armstrong is with the David Geffen School of Medicine at the University of California, Los Angeles in Los Angeles, California.
[EFFICACY AND SAFETY OF ENFORTUMAB VEDOTIN IN ADVANCED UROTHELIAL CARCINOMA TREATMENT: AN INITIAL EXPERIENCE IN A SINGLE INSTITUTION].
Nihon Hinyokika Gakkai Zasshi
January 2025
Department of Urology, Kurume University School of Medicine.
(Purpose) Enfortumab vedotin has been available as a third-line treatment for advanced urothelial carcinoma in Japan since December 2021. While the treatment is expected to improve the outcome of advanced urothelial carcinoma, concerns regarding adverse events do exist. We report here our initial experience of the use of enfortumab vedotin as a third-line therapy in patients with advanced urothelial carcinoma.
View Article and Find Full Text PDF[UPFRONT DOCETAXEL WITH ANDROGEN DEPRIVATION THERAPY IN MALES WITH HIGH-VOLUME METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER: RESULTS OF A SINGLE-INSTITUTION SERIES].
Nihon Hinyokika Gakkai Zasshi
January 2025
Department of Urology, Jikei University of Medicine.
(Objective) This study aimed at evaluating the efficacy and safety of upfront docetaxel (DTX) treatment and androgen deprivation therapy (ADT) in male patients with high-volume metastatic castration-sensitive prostate cancer (HV-mCSPC). (Methods) This retrospective study was conducted using the medical records of 30 patients treated for HV-mCSPC by using upfront DTX treatment along with ADT at Atsugi City Hospital between December 2015 and December 2022. The patient characteristics, demographics, oncological outcomes, adverse events, and sequential therapy were evaluated.
View Article and Find Full Text PDFComparative efficacy of minoxidil alone versus minoxidil combined with low-level laser therapy in the treatment of androgenic alopecia: a systematic review and meta-analysis.
J Dermatolog Treat
December 2025
Dermatology Department, King Fahad Hospital Jeddah, Jeddah, Saudi Arabia.
Objective: This systematic review evaluates the efficacy of minoxidil alone versus minoxidil with low-level laser therapy (LLLT) for androgenic alopecia.
Study Design: systematic review and meta-analysis.
Methods: An online search of PubMed, Web of Science, and MEDLINE was conducted.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!